title: Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?
abstract: The identification of noninvasive biomarkers is still one of the major issue for gastroenterologists dealing with inflammatory bowel disease patients, due to the chronicity of these conditions and the early onset of symptoms in the majority of cases. Research attention has focused mainly on fecal proteins, especially calprotectin and lactoferrin, and most of the published data are reassuring about their applicability in the diagnosis and monitoring of these patients. However, there are still pending questions regarding the reliability of fecal proteins especially in the era of mucosal healing and biologics.
authors.affiliation: Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, via Giustiniani 2, Padua, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Caccaro
authors.forename: Renata
authors.initials: R
authors.lastname: D'Incà
authors.forename: Surajit
authors.initials: S
authors.lastname: Pathak
authors.forename: Giacomo Carlo
authors.initials: GC
authors.lastname: Sturniolo
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D005243:Feces / Q000737:chemistry; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000378:metabolism*; D007781:Lactoferrin / Q000378:metabolism*; D039841:Leukocyte L1 Antigen Complex / Q000378:metabolism*; D011379:Prognosis
chemical_list: D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex; D007781:Lactoferrin